Zoetis has received marketing authorization from the European Commission for Lenivia, an antibody therapy designed to reduce pain associated with osteoarthritis in dogs. The approval clears the way for the product to be offered across European Union member states and means veterinarians may now consider the single‑injection treatment — described by the company as providing up to three months of relief from a single dose — as part of clinical care for canine osteoarthritis. Coverage from Zoetis has highlighted this story.

The authorization marks a regulatory milestone for Zoetis and for veterinary professionals who treat chronic pain in companion animals. Zoetis said the decision will allow it to introduce Lenivia into European markets; the company framed the authorization as a step forward in managing osteoarthritis pain in dogs and in expanding the options available to clinicians and owners.

Lenivia is presented by Zoetis as an antibody therapy intended specifically to reduce pain associated with osteoarthritis. According to the company, the treatment is delivered as a single injection that can provide approximately three months of pain relief, a dosing profile industry observers say could change how clinicians schedule follow‑up care and how owners adhere to treatment plans for their animals. Reporting by Veterinaryjournal offers additional detail on this case.

Veterinary regulators and clinicians will now assess how Lenivia fits into clinical practice, including how and when it should be used relative to other pain‑management strategies. The European Commission authorization gives member states the ability to make the therapy available in accordance with national prescribing rules and professional guidance, and veterinary bodies will review the product’s role in standard care pathways for affected animals.

Regulatory background and assessment details are available in documents from the European Medicines Agency and related materials, which provide context on marketing authorizations and the technical evaluations that support them. Zoetis has also published information on its own press pages outlining regulatory milestones and its plans for bringing Lenivia to market in Europe.

Industry commentators have highlighted the potential practical impact of a three‑month, single‑injection therapy. For clinics, the dosing interval could simplify scheduling and reduce the frequency of visits required for ongoing pain management; for owners, a longer‑acting option may influence adherence to prescribed treatment regimens and improve overall continuity of care for chronically affected dogs. As covered by Europa Eu, readers can explore more context around the event.

This claim about rollout and supply management is not explicitly confirmed in the available official sources, though it is a reasonable inference given standard industry practice. The company’s existing distribution and sales networks for animal health products will be used to make Lenivia available to veterinary clinics, subject to the regulatory and professional frameworks that govern prescribing and dispensing in each country.

The European Commission’s marketing authorization applies across member states, enabling veterinarians to consider Lenivia for dogs with osteoarthritis in line with local rules. Regulatory assessment documents and company announcements are expected to provide further technical and procedural background on the therapy, including indications, administration details and any usage restrictions.

Veterinary clinics and dog owners seeking more information on Lenivia and its availability can refer to Zoetis’ official communications and to materials published by European regulatory agencies. Those sources will contain the most current information on approved indications, administration guidance and the practical steps for obtaining the therapy within different national systems.

The European Commission authorization represents the latest regulatory development for Zoetis as it expands its portfolio of treatments for companion animals. With Lenivia now authorized for marketing across the region, the company and clinicians will move to implement the product within the frameworks set by national veterinary authorities and professional guidance bodies.

Source

Original reporting: view the original article.